r Remote ischaemic preconditioning (RIPC), induced by brief bouts of ischaemia followed by reperfusion, confers vascular adaptations that protect against subsequent bouts of ischaemia; however, the effect of RIPC repeated over several days on the human microcirculation is unknown.
Introduction
Ischaemic preconditioning (IPC), or a cycle of 3-4 brief periods of ischaemia followed by reperfusion, protects tissues against subsequent ischaemic damage (Murry et al. 1986) . In addition to the local effects of IPC, protection against tissue damage is evident in areas distant from where the ischaemic stimulus occurred (Przyklenk et al. 1993) . This type of IPC, called remote ischaemic preconditioning (RIPC), can be induced in humans using a peripheral limb as a preconditioning stimulus (Kharbanda et al. 2002) . A single bout of RIPC in the contralateral limb confers ischaemic tolerance and improves endothelial function in conduit vessels, as measured by flow-mediated dilatation (FMD) (Loukogeorgakis et al. 2005; Luca et al. 2013) . Following a single RIPC bout, there is an immediate and a delayed window of protection that likely persists for ß3-4 days (Bolli, 2000; Loukogeorgakis et al. 2005) . Repeated bouts of RIPC, performed over several days, may confer vascular adaptations lasting a week or more (Jones et al. 2014; Thijssen et al. 2016) . The mechanisms underlying these adaptations may differ depending on whether the stimulus was an acute RIPC bout as opposed to multiple bouts of RIPC.
In conduit and resistance vessels, repeated bouts of RIPC implemented over a 1-8 week period increased endothelial function (Kimura et al. 2007; Luca et al. 2013; Jones et al. 2014 Jones et al. , 2015 Liang et al. 2015) . It has also been demonstrated that the maximal forearm blood flow response to acetylcholine is increased after 4 weeks of RIPC (Kimura et al. 2007) . However, selective cyclooxygenase-2 inhibition does not alter the FMD response after repeated RIPC (Luca et al. 2013) . Collectively, these data suggest that the endothelial adaptations resulting from repeated RIPC may be NO mediated. Additionally, 4 weeks of RIPC increases circulating endothelial progenitor cells and vascular endothelial growth factor (Kimura et al. 2007) , thereby indicating that repeated RIPC may also stimulate changes in microvascular structure.
In vivo assessment of microvascular function can be performed non-invasively by Laser Doppler flowmetry measurements of skin blood flow responses to thermal stimuli (Holowatz et al. 2008; Minson, 2010) . Localized heating of skin elicits a biphasic vasodilatation (VD) response characterized by an initial axon reflex response followed by a longer lasting plateau phase that is mediated primarily by NO and endothelial-derived hyperpolarizing factors (EDHF) (Kellogg et al. 1999; Minson et al. 2001 Minson et al. , 2002 Brunt & Minson, 2012; Johnson et al. 2014 ). The few in vivo studies assessing microvascular function following RIPC suggest that baseline cutaneous blood flow, in a thermoneutral environment, is increased following an acute RIPC bout (Kraemer et al. 2011) or following repeated RIPC (Jones et al. 2014) . There is no effect of repeated RIPC on the VD response to localized heating of skin (Jones et al. 2014) ; however, this finding may have been obscured by the heating protocol used and method of normalizing the VD response. Nevertheless, the extent to which repeated RIPC affects the cutaneous microcirculation and the mechanisms underlying these adaptations remains unclear.
Using skin as a model for assessing microvascular responses, the purpose of this study was to assess the local heating response after 7 days of RIPC and examine the role of nitric oxide (NO) as a potential mechanism affected by RIPC. Based upon previous work in animal models demonstrating that NO confers RIPC-induced cardioprotection (Rassaf et al. 2014; Aggarwal et al. 2016) , we hypothesized that the magnitude of the cutaneous VD response to localized heating, when normalized as a percentage of maximum, would be increased following seven consecutive days of RIPC sessions. We further hypothesized that there would be increased NO function following repeated RIPC, as demonstrated by greater attenuation of VD responses with intradermal perfusion of a nitric oxide synthase (NOS) inhibitor.
Methods

Ethical approval
All experimental procedures were approved by the Food and Drug Administration (FDA IND No. 127 630) and the Institutional Review Board at Des Moines University . All procedures conformed to the standards set by the latest revision of the Declaration of Helsinki, except for registration in a database, with each participant providing informed, written consent.
Subjects
Ten healthy young men and women (age = 23 ± 1 years, 6 males, 4 females; mean BMI = 23 kg/m 2 ) participated in the study. All subjects were normotensive, non-smokers, not obese according to body mass index, had no history of chronic skin diseases or skin allergies, and were not taking medications or supplements that alter cardiovascular or thermoregulatory control. On the day of an experiment, subjects arrived at the laboratory after fasting (>3 h), abstention from alcohol, caffeine, and vitamin supplementation (>12 h), and refrained from novel or strenuous physical activity (>24 h).
Microvascular response to local heating
The experimental protocol was designed to test the effects of seven consecutive days of RIPC on skin microvascular responses to local heating (Fig. 1) . Each daily RIPC session consisted of 4 bouts of 5 min of arm ischaemia, via upper arm cuff inflations to ß220 mmHg, with each bout separated by 5 min of no cuff pressure. On the contralateral arm, measurements of cutaneous microvascular function were performed before, 1 day after (>24 h but < 48 h), and 1 week after RIPC administration.
On the morning of a microvascular assessment (08.00-13.00 h), participants arrived at the laboratory (room temperature = 22°C) and were positioned in a semi-recumbent position prior to instrumentation. Two microdialysis (MD) fibres (10 mm, 30 kDa molecular mass cut-off membrane, MD 2000; Bioanalytical Systems, West Lafayette, IN, USA) were aseptically placed in the dermis of the ventral forearm for localized drug administration. Immediately before use, sodium nitroprusside (SNP) and N G -nitro-L-arginine methyl ester (L-NAME) were weighed in the laboratory (Mettler-Toledo MS105; Columbus, OH, USA), dissolved in lactated Ringer solution, and filtered with syringe microfilters (Acrodisc; Pall, Ann Arbor, MI, USA). Local heating units were attached to the skin surface over each MD site and were set to a thermoneutral skin temperature of 33°C. A multifibre integrated laser Doppler flowmetry probe was placed within each local heating unit to continuously measure red blood cell flux, an index 1977). Arterial blood pressure was measured every 10 min using an automated system (Suntech Tango M2, Morrisville, NC, USA) that was verified with brachial auscultation. Heart rate was continuously collected using a lead II electrocardiogram (CT-1000 cardiotachometer, CWE inc, Ardmore, PA, USA). After instrumentation and resolution of the local hyperaemia response secondary to MD fibre placement, each MD site was randomly assigned for continuous perfusion (2.0 μl/min) of either Ringer solution (control) or 20 mM L-NAME to competitively inhibit NOS (Baby Bee Syringe Drive and Hive Controlled; Bioanalytical Systems). Greater concentrations of L-NAME have not been demonstrated to further inhibit NO function in skin (Minson et al. 2001 (Minson et al. , 2002 .
To better focus upon the NO-mediated vascular response to repeated RIPC, we implemented a heating protocol that is more reliant upon NO (i.e. ß70% of the VD response at plateau) (Choi et al. 2014) . Thus, after ß60-90 min of baseline perfusion of the assigned drug, local heating commenced by increasing the temperature at both MD skin sites from a 33°C to 39°C at the rate of 0.1°C every second (Choi et al. 2014) . After skin blood flow increased and reached a plateau (after ß30-45 min), 20 mM L-NAME was added to the control site to assess NO-mediated VD. To determine percentage NO contribution to local heating, L-NAME perfusion began at the control site after a plateau in the VD response occurred, after ß30-45 min of heating, to allow for a within-site comparison. L-NAME was perfused at a second MD site throughout the protocol for between-site comparisons. Absolute NO-mediated VD was determined as the cutaneous vascular conductance (flux/mmHg) of the local heating plateau minus the post-L-NAME plateau. After L-NAME perfusion, maximum cutaneous VD was elicited at both MD sites by increasing local heaters to a temperature of 43°C and concomitantly beginning perfusion of 28 mM SNP, a NO-donor. A protocol schematic and a representative local heating response for both MD sites is illustrated in Fig. 1 .
Data analysis
All data were collected at 1000 Hz and stored for further analysis (LabChart v8.0, Powerlab 16/35; ADinstrument, Bella Vista, NSW, Australia). The laser Doppler flux (LDF) data was processed as 1 s averages taken at 4 s intervals throughout the protocol. Flux values were averaged over 2 min periods at baseline, during the local heating plateau, post L-NAME plateau, and after maximal VD was elicited. Cutaneous vascular conductance (CVC) was calculated as the mean LDF divided by mean arterial pressure (diastolic pressure + 1/3 pulse pressure) and expressed as an absolute CVC value (flux/mmHg). Percentage NO contribution was calculated as ((heat plateau -L-NAME plateau)/ heat plateau) × 100. For NO contribution and each phase of local heating, one-way repeated measures ANOVA followed by post hoc analysis using Fisher's Least Significant Difference test were conducted to detect mean CVC differences between pre, post and 1 week post RIPC (SPSS version 24, IBM, Armonk, NY, USA). Statistical significance was set at α = 0.05. An a priori sample size analysis indicated that 10 participants were needed to detect significant differences in CVC at p < 0.05 and 80% power (Minson et al. 2002; Lang & Kolb, 2015) . Data are presented as means ± SEM except for data illustrating individual subject changes with RIPC that include group means and standard deviations (Fig. 2) .
Results
Mean arterial pressure was not different between pre (84 ± 2 mmHg), post (83 ± 1 mmHg), and 1 week post repeated RIPC (81 ± 2 mmHg). Heart rate was also unchanged between pre (59 ± 3 bpm), post (61 ± 2 bpm), and 1 week post RIPC (59 ± 2 bpm). Absolute CVC values (flux/mmHg) at each MD site during baseline, local heating plateau (T loc = 39°C), and NO-mediated VD were not different following RIPC (p > 0.05) (Table 1) . Furthermore, RIPC did not affect the percentage contribution of NO to the local heating plateau either within the control site or between MD fibre sites (p > 0.05). However, maximal cutaneous VD (i.e. CVC max ), elicited by concomitant local heating (T loc = 43°C) and SNP infusion, increased in both the control and L-NAME MD sites immediately following 7 days of RIPC (pre vs. post; Control: 2.55 ± 0.13 vs. 3.61 ± 0.38; L-NAME: 2.48 ± 0.21 vs. 3.11 ± 0.24 flux/mmHg, p < 0.05). Maximal VD remained elevated in both MD sites 1 week after ending RIPC treatment (Control: 3.21 ± 0.28 flux/mmHg, p = 0.10 vs. pre; L-NAME: 3.00 ± 0.25 flux/mmHg, p < 0.05 vs. pre). Individual changes in the maximal VD response following 7 days of RIPC are illustrated at the control site ( Fig. 2A) and the L-NAME site (Fig. 2B) . When the data were expressed as a percentage of maximal VD (%CVC max ), the local heating plateau was not increased immediately following 7 days of RIPC (pre vs. post; Control: 70.5 ± 7.0 vs. 52.2 ± 6.9; L-NAME: 18.7 ± 3.8 vs. 16.7 ± 3.2 %CVC max , p > 0.05 vs. pre) or 1 week post RIPC treatment (Control: 55.6 ± 5.8; L-NAME: 14.7 ± 2.4 %CVC max , p > 0.05 vs. pre). When normalized to maximum CVC, the NO contribution to the local heating plateau was also not different after RIPC (Control: pre = 49.7 ± 5.7, post = 40.4 ± 6.2, 1 week post = 43.2 ± 5.0 %CVC max , p > 0.05).
Discussion
The purpose of this study was to determine whether seven daily bouts of RIPC affected the cutaneous microvascular response to local heating. We found that the maximal dilatation response, in both the control and the L-NAME site, was augmented by ß25-50% after RIPC and remained significantly elevated 1 week after RIPC. Contrary to our hypothesis, NO function was not affected after repeated RIPC. This was evidenced by (1) no change in the local heating plateau using a protocol (T loc = 39°C) demonstrated to elicit cutaneous VD principally by NO (Choi et al. 2014) , and (2) no change in the NO contribution to the local heating plateau determined with L-NAME perfusion either within the control site or between the control and a skin site continuously perfused with L-NAME. Collectively, these data suggest that repeated bouts of RIPC augments maximal vasodilatory capacity in the cutaneous microvasculature yet the underlying mechanism for this improvement is independent of NO. By extension, these findings suggest that the adaptations to repeated RIPC are either endothelium independent, modulated by other endothelial-dependent factors such as EDHF, or both.
The cutaneous local heating response typically consists of an immediate initial dilatation, followed by a nadir, and then a plateau in skin blood flow (Fig. 1) . The VD response corresponding to the local heating plateau is primarily mediated by NO and EDHF (Kellogg et al. 1999; Minson et al. 2001 Minson et al. , 2002 Brunt & Minson, 2012; Choi et al. 2014; Johnson et al. 2014) . Few studies have examined how RIPC affects the skin microvasculature (Kraemer et al. 2011; Jones et al. 2014 Jones et al. , 2015 . One study found that an acute RIPC bout increases tissue oxygen saturation and capillary blood flow (Kraemer et al. 2011) . Jones et al. (2014) found that baseline cutaneous vascular conductance (CVC) was increased following 7 days of repeated RIPC and remained elevated 1 week after the last RIPC bout. However, this J Physiol 597.3 increase in baseline CVC was not observed in the current study and was also not seen after 3 bouts of RIPC per week over an 8 week period (Jones et al. 2015) . Furthermore, the studies by Jones et al. found that the VD response to localized heating (T loc = 42°C) remained unchanged (Jones et al. 2014 (Jones et al. , 2015 . Considering that the heating plateau at 42°C produces a ß90% dilatation (Minson et al. 2001; Choi et al. 2014 ), a ceiling effect may have occurred that may have masked any putative changes following RIPC. We used a similar 7 day RIPC protocol and found that the local heating response was unaffected despite using a lower local heating temperature (T loc = 39°C). Although these data collectively indicate that repeated RIPC does not affect the magnitude of the local heating response, we cannot exclude the notion that RIPC may affect the contribution of various endothelium-derived mechanisms that contribute to the VD response.
The underlying mechanisms for RIPC are likely to depend upon the time elapsed after the last ischaemic bout. The vascular protection that occurs after an acute bout of RIPC follows a biphasic pattern that consists of an 'immediate window' of protection that lasts for ß3 h followed by a 'delayed window' where protection resumes ß12-24 h after the ischaemic stimulus and continues for ß3 days (Bolli, 2000; Loukogeorgakis et al. 2005) . The underlying mechanisms for each of these windows of cardiovascular adaptation appear to be different but have yet to be clearly elucidated, particularly in humans. Previous work in animal models has demonstrated that NO has an important contributory role in conferring RIPC-induced cardioprotection particularly during the 'delayed window' (Rassaf et al. 2014; Aggarwal et al. 2016) , although there are studies that have not observed this (Petrishchev et al. 2001) . The putative role of NO appears to be isoform specific, with shear stress-mediated eNOS activation having a greater role in the immediate window of RIPC whereas iNOS is more important in the delayed window (Li et al. 2004; Aggarwal et al. 2016) . Using a non-specific NOS inhibitor, we did not observe an increase in either the local heating plateau or in NO-mediated VD following two post-RIPC measurements, one collected 24-36 h after and the second 1 week after the last RIPC session.
The lack of evidence for NO contribution may be due to the window in which microvascular measurements were collected. In the current study, NO function was not affected during the 'delayed window' or with repeated RIPC; however, there may be a role for NO in triggering adaptations during the 'immediate window' (Depre et al. 2010) . Alternatively, the number or duration of ischaemic bouts may affect NO function. In a protocol designed to maximize shear stress, 5 s forearm occlusion interspersed with 10 s rest for 30 min performed over a 6 week period, increased the NO contribution to the local heating plateau (Hodges et al. 2018) . However, these responses were measured in the same arm and thus, the 'remote' effects were not addressed. It is possible that repeated RIPC may yet increase NO to have an effect on larger vessels or other vascular beds. Our data would suggest that other endothelial mediators, such as EDHF, or endothelium-independent mechanisms may be altered following repeated RIPC; however, this requires further investigation.
The present study demonstrated that the vascular adaptations that accompany RIPC are independent of NO and may have a structural or endothelial-independent component. A typical means of determining maximal CVC is by increasing the local temperature to 43°C and concomitantly infusing intradermal SNP (Johnson et al. 2014) . We found that this dilatation response, in both the control and the L-NAME site, was augmented by ß25-50% after RIPC and remained significantly elevated 1 week after RIPC. Thus, the increased maximal dilatation response was evident within the delayed window and after the cumulative effect of repeated bouts of RIPC, respectively. While the magnitude of the response varied among the subjects, nearly all individual skin sites exhibited an increase in max CVC post-RIPC. The reason for this variability is unclear but may be due to other co-existing factors that could affect blood flow mechanisms during the 1 week period of RIPC, such as physical activity or repeated exposures to heat (Brunt et al. 2016) .
Alterations in vascular smooth muscle function and angiogenesis may contribute to the augmented NO-independent VD observed in the current study. Vascular endothelial growth factor (VEGF) and endothelial progenitor cells are increased following repeated RIPC (Kimura et al. 2007; Liang et al. 2015) . Following an ischaemic bout, endothelial cells begin mitosis 1 day later and proliferation several days thereafter (Hayashi et al. 2003) . The repeated RIPC protocol used in the current study would have coincided with this time frame; however, full expression of an angiogenic response may not have occurred (Hayashi et al. 2003) . In vascular smooth muscle, there is evidence that blocking ATP-sensitive potassium channels (K ATP ) channels with glibenclamide reduces the FMD response after RIPC (Loukogeorgakis et al. 2007 ). As such, K ATP channels influenced by RIPC may attenuate intracellular calcium concentration in smooth muscle and augment the maximal cutaneous VD response. Whether RIPC affects other potassium channels that have been demonstrated to have a greater functional role in the cutaneous local heating response remains unknown (Brunt & Minson, 2012; Choi et al. 2014; Fujii et al. 2018) .
The data from the present study support using a skin model to identify underlying mechanisms that explain general microvascular adaptations resulting from RIPC administration in humans. Altered cutaneous reactivity to thermal stimuli is an indicator of more global changes in microvascular function (Rossi et al. 2006; Holowatz et al. 2008; Minson, 2010) . Thus, skin microvascular adaptations may explain how function may be altered in the coronary vascular bed (Abularrage et al. 2005; Khan et al. 2008) . The attractiveness of an easy-to-employ and non-pharmacological intervention that improves microvascular function and confers ischaemic tolerance to protect tissues from subsequent ischaemic bouts is important clinically and warrants further investigation (Thijssen et al. 2016 ).
Limitations of the study
Sodium nitroprusside was used in the study design to elicit a maximal dilatation response (CVC max ) as a point from which to normalize the heating data. Cutaneous local heating data is a more reproducibly represented using % CVC max (Tew et al. 2011) . However, absolute CVC was used in the current study because the maximal CVC was increased after RIPC in most subjects and at most skin microdialysis sites (Fig. 2) . While this result highlights the effect of repeated RIPC, the greater subject variability seen here may be due to representing data as absolute CVC. Although there is inherently some variability in skin responses between MD sites, this limitation is minimized by a study design that incorporated within-site comparisons for assessing NO function and using a second skin site to assess maximal cutaneous VD changes with RIPC.
In conclusion, maximal dilatory capacity was increased by ß25-50% immediately following repeated RIPC and remained significantly elevated 1 week after stopping RIPC. This suggests that cutaneous vascular adaptations are occurring with repeated RIPC. However, the NO contribution to the cutaneous VD to local heating was not altered following repeated RIPC, which suggests a role for other mechanisms that may explain the vascular adaptations after repeated RIPC.
Translational perspective
Remote ischaemic preconditioning (RIPC), induced by a cycle of 3-4 brief periods of limb ischaemia followed by reperfusion, may elicit adaptations that protect distant tissues and organs from ischaemic damage. Considering that rehabilitation and prevention of secondary ischaemic events cost ß$34 billion in the USA alone, RIPC is an appealing intervention because it can be easily and inexpensively administered. Although larger clinical trials have challenged the efficacy of RIPC in humans, these studies have also highlighted the need for an experimental model to control for potentially obfuscating factors (e.g. method of RIPC administration, medications, age, fitness level, etc.) while still examining underlying mechanisms. In the current study, we used the skin as an in vivo and accessible model representing coronary microvascular function. The primary finding of this study was that cutaneous microvascular function was improved following seven daily bouts of RIPC in young, healthy adults. Although the nitric oxide and localized heating response was not affected after repeated RIPC, the maximal cutaneous dilatation response was augmented by ß25-50% after RIPC and remained significantly elevated 1 week after RIPC. Collectively, these findings demonstrate that repeated bouts of RIPC augment maximal vasodilatory capacity in the microvasculature yet the underlying mechanism is independent of nitric oxide. These data also suggest that the skin microvascular model used in the current study is useful in dissecting mechanisms of RIPC and informing future studies to determine how RIPC could be administered clinically to optimize its protective effects against ischaemic damage.
